Stock market today: S&P 500 falls as job cuts stoke economic fears, tech stutters
Investing.com - H.C. Wainwright reiterated a Buy rating and $16.00 price target on Cabaletta Bio Inc. (NASDAQ:CABA), a clinical-stage biotech with a market cap of $226 million, following the presentation of additional positive clinical data from the RESET trials at ACR Convergence 2025. According to InvestingPro data, the stock has shown remarkable momentum with a 117.56% return over the past six months, while analysts maintain a strong bullish consensus with price targets ranging from $2 to $22.
The data presented at the conference, which runs from October 24-29, covered RESET trials for Myositis, SSc, and SLE. H.C. Wainwright highlighted Cabaletta’s emphasis on rese-cel’s superior safety profile, noting that among the first 32 patients treated, 66% did not experience any cytokine release syndrome (CRS) events. InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 4.78, though it’s currently operating at a loss with significant R&D investments.
The firm pointed out that very few severe immune effector cell-associated neurotoxicity syndrome (ICANS) cases have been reported in Cabaletta’s trials, with one occurrence in a lupus patient who had a prior episode of pericarditis before treatment in August 2024, and a grade 3 case in the SSc cohort reported in March 2025.
By comparison, Bristol Myers Squibb reported at the ACR that 73.1% of SLE patients receiving its CD19 cell therapy at the recommended dose experienced grade 1 or grade 2 CRS, while one patient experienced a grade 3 event. H.C. Wainwright noted that Cabaletta employs a weight-adjusted dosing strategy, unlike competitors who use a fixed dose.
As of late October, Cabaletta has enrolled 76 patients across all cohorts and dosed 50 of them, with efficacy data available for 28 patients presented at ACR. Additional efficacy data from RESET-MG will be presented at AANEM 2025 on Wednesday. InvestingPro analysis indicates the stock is currently undervalued, with 12 additional exclusive ProTips available to subscribers, including detailed insights on the company’s financial health and growth prospects. Get access to the comprehensive Pro Research Report covering what really matters about CABA and 1,400+ other stocks through intuitive visuals and expert analysis.
In other recent news, Cabaletta Bio has been the focus of several analyst updates. Guggenheim has lowered its price target for the company to $15, down from $25, due to share dilution following a $100 million capital raise. This capital raise, which extends Cabaletta’s cash runway into the second half of 2026, involved issuing 50 million shares and an additional 50 million warrants. Jefferies also adjusted its price target for Cabaletta Bio from $28 to $14, maintaining a Buy rating, and noted the company’s promising position in the cell therapy market for autoimmune diseases. Cantor Fitzgerald reiterated its Overweight rating with a $15 price target, highlighting a case study involving CAR-T cell therapy for Ulcerative Colitis. Jefferies resumed coverage on Cabaletta Bio with a Buy rating and a $14 price target, following the presentation of clinical trial data at a recent conference. These developments reflect ongoing interest and varying perspectives among analysts regarding Cabaletta Bio’s financial and clinical progress.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.